JP2012532624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532624A5 JP2012532624A5 JP2012520100A JP2012520100A JP2012532624A5 JP 2012532624 A5 JP2012532624 A5 JP 2012532624A5 JP 2012520100 A JP2012520100 A JP 2012520100A JP 2012520100 A JP2012520100 A JP 2012520100A JP 2012532624 A5 JP2012532624 A5 JP 2012532624A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- itnk
- cell
- pro
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims 21
- 230000014509 gene expression Effects 0.000 claims 6
- 101150106964 Bcl11b gene Proteins 0.000 claims 5
- 101100493744 Mus musculus Bcl11b gene Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- -1 IL2Rβ Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 210000003967 CLP Anatomy 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 101150092640 HES1 gene Proteins 0.000 claims 1
- 101150003775 HNF1A gene Proteins 0.000 claims 1
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 1
- 101000979599 Homo sapiens Protein NKG7 Proteins 0.000 claims 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 1
- 101000760175 Homo sapiens Zinc finger protein 35 Proteins 0.000 claims 1
- 101150111463 ID2 gene Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 1
- 101150069255 KLRC1 gene Proteins 0.000 claims 1
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 claims 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 claims 1
- 101001049180 Mus musculus Killer cell lectin-like receptor subfamily B member 1C Proteins 0.000 claims 1
- 101100181101 Mus musculus Klra3 gene Proteins 0.000 claims 1
- 101100537555 Mus musculus Tnfrsf9 gene Proteins 0.000 claims 1
- 101100369993 Mus musculus Tnfsf10 gene Proteins 0.000 claims 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000001759 Notch1 Receptor Human genes 0.000 claims 1
- 108010029755 Notch1 Receptor Proteins 0.000 claims 1
- 108010056995 Perforin Proteins 0.000 claims 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims 1
- 102100023370 Protein NKG7 Human genes 0.000 claims 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 1
- 102100024672 Zinc finger protein 35 Human genes 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 229930192851 perforin Natural products 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22577909P | 2009-07-15 | 2009-07-15 | |
| GB0912287A GB0912287D0 (en) | 2009-07-15 | 2009-07-15 | Cells, compositions and methods |
| US61/225,779 | 2009-07-15 | ||
| GB0912287.0 | 2009-07-15 | ||
| GBGB1006649.6A GB201006649D0 (en) | 2010-04-21 | 2010-04-21 | Cells, compositions and methods |
| GB1006649.6 | 2010-04-21 | ||
| PCT/GB2010/051158 WO2011007176A1 (en) | 2009-07-15 | 2010-07-15 | Cells, compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012532624A JP2012532624A (ja) | 2012-12-20 |
| JP2012532624A5 true JP2012532624A5 (https=) | 2013-09-05 |
Family
ID=43448979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520100A Pending JP2012532624A (ja) | 2009-07-15 | 2010-07-15 | 細胞、組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120288484A1 (https=) |
| EP (1) | EP2454361A1 (https=) |
| JP (1) | JP2012532624A (https=) |
| WO (1) | WO2011007176A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103409466B (zh) * | 2013-05-27 | 2015-01-21 | 中国科学院广州生物医药与健康研究院 | 一种使bcl11b蛋白降解的方法 |
| US20190185852A1 (en) * | 2016-05-05 | 2019-06-20 | M. Mahmood Hussain | Therapeutically modulating apob and apoai |
| CN112574952B (zh) * | 2019-09-30 | 2025-04-15 | 英基生物医药(香港)有限公司 | 一种工程化人体免疫细胞、其制备方法及应用 |
| CN119842626A (zh) * | 2019-12-27 | 2025-04-18 | 昭泰英基生物医药（香港）有限公司 | 一种工程化免疫杀伤细胞、其制备方法及应用 |
| CN111607569A (zh) * | 2020-06-01 | 2020-09-01 | 广东昭泰体内生物医药科技有限公司 | 一种基于CRISPR/Cas9重编程ITNK细胞的方法 |
| CN111849919A (zh) * | 2020-07-24 | 2020-10-30 | 英基生物医药(香港)有限公司 | 一种具有抗病毒活性的工程化免疫细胞及其构建方法和应用 |
| CA3216709A1 (en) * | 2021-05-13 | 2022-11-17 | Katharine C. Hsu | Nkg2c+ t cells and methods of use thereof |
| JP2024534981A (ja) * | 2021-09-10 | 2024-09-26 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | 誘導ナチュラルキラー細胞の製造方法及びその使用 |
| CN119909172B (zh) * | 2025-01-15 | 2026-03-13 | 华中科技大学同济医学院附属协和医院 | 过表达slc29a1用于增强t细胞内外活性的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999049881A2 (de) * | 1998-03-27 | 1999-10-07 | Gabriele Multhoff | Verwendung von hsp70 protein |
| JP2005320309A (ja) * | 2004-05-02 | 2005-11-17 | Hokkaido Technology Licence Office Co Ltd | 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬 |
-
2010
- 2010-07-15 JP JP2012520100A patent/JP2012532624A/ja active Pending
- 2010-07-15 EP EP10735072A patent/EP2454361A1/en not_active Withdrawn
- 2010-07-15 US US13/384,081 patent/US20120288484A1/en not_active Abandoned
- 2010-07-15 WO PCT/GB2010/051158 patent/WO2011007176A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532624A5 (https=) | ||
| Yu et al. | Preconditioning with interleukin‐1 beta and interferon‐gamma enhances the efficacy of human umbilical cord blood‐derived mesenchymal stem cells‐based therapy via enhancing prostaglandin E2 secretion and indoleamine 2, 3‐dioxygenase activity in dextran sulfate sodium‐induced colitis | |
| Kuzmina et al. | Multipotent mesenchymal stromal cells for the prophylaxis of acute graft‐versus‐host disease—a phase II study | |
| Uccelli et al. | Mesenchymal stem cells: a new strategy for immunosuppression? | |
| Capucha et al. | Distinct murine mucosal Langerhans cell subsets develop from pre-dendritic cells and monocytes | |
| Sinkovics et al. | Human natural killer cells: a comprehensive review | |
| Aversa et al. | Haploidentical hematopoietic stem cell transplantation with a megadose T-cell–depleted graft: harnessing natural and adaptive immunity | |
| US20210008110A1 (en) | Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions | |
| JP2012532624A (ja) | 細胞、組成物および方法 | |
| Zhu et al. | Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen–mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia | |
| KR101968184B1 (ko) | 저산소 조건을 이용한 면역세포의 증식 배양 방법 | |
| WO2013111969A1 (ko) | 탄시논을 유효성분으로 함유하는 자연살해세포 분화 또는 활성 증진용 조성물 | |
| US10517937B2 (en) | Immunotherapy for the treatment of cancer | |
| JP2022023136A5 (https=) | ||
| US20230011889A1 (en) | Genetically engineered double negative t cells as an adoptive cellular therapy | |
| Zhang et al. | Enhanced antitumor immunity by murine cytokine activated T lymphocytes after cocultured with bone marrow derived dendritic cells pulsed with whole tumor lysates | |
| Chen et al. | Viral‐Directed Augmentation of Kupffer Cell Cross‐Presentation Provokes Antitumor Immunity Against Liver Metastasis | |
| WO2014133090A1 (ja) | 脳腫瘍治療のための多能性幹細胞 | |
| Zhang et al. | Hematopoietic stem and immune cells in chronic HIV infection | |
| RU2009129507A (ru) | Способ лечения онкологических заболеваний | |
| Fousteri et al. | Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure | |
| Rejeski et al. | Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DCleu mediated T-cell activation and on-target/off-tumor toxicity | |
| KR20120095320A (ko) | 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 독성 억제를 위한 세포보호용 조성물 | |
| EP3204020B1 (en) | Treating viral hemorrhagic fever with nk-92 cells | |
| Melamed | Homeostatic regulation of aging and rejuvenation in the B lineage cells |